EP1267898A4 - Bile acid containing prodrugs with enhanced bioavailability - Google Patents

Bile acid containing prodrugs with enhanced bioavailability

Info

Publication number
EP1267898A4
EP1267898A4 EP01926709A EP01926709A EP1267898A4 EP 1267898 A4 EP1267898 A4 EP 1267898A4 EP 01926709 A EP01926709 A EP 01926709A EP 01926709 A EP01926709 A EP 01926709A EP 1267898 A4 EP1267898 A4 EP 1267898A4
Authority
EP
European Patent Office
Prior art keywords
acid containing
bile acid
containing prodrugs
enhanced bioavailability
bioavailability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01926709A
Other languages
German (de)
French (fr)
Other versions
EP1267898A2 (en
Inventor
James E Polli
Andrew Coop
Dean Y Maeda
Kimberley A Lentz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of EP1267898A2 publication Critical patent/EP1267898A2/en
Publication of EP1267898A4 publication Critical patent/EP1267898A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP01926709A 2000-04-07 2001-04-06 Bile acid containing prodrugs with enhanced bioavailability Ceased EP1267898A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19585400P 2000-04-07 2000-04-07
US195854P 2000-04-07
US26990601P 2001-02-21 2001-02-21
US269906P 2001-02-21
PCT/US2001/011327 WO2001076531A2 (en) 2000-04-07 2001-04-06 Bile acid containing prodrugs with enhanced bioavailability

Publications (2)

Publication Number Publication Date
EP1267898A2 EP1267898A2 (en) 2003-01-02
EP1267898A4 true EP1267898A4 (en) 2006-02-01

Family

ID=26891401

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01926709A Ceased EP1267898A4 (en) 2000-04-07 2001-04-06 Bile acid containing prodrugs with enhanced bioavailability

Country Status (5)

Country Link
EP (1) EP1267898A4 (en)
JP (1) JP2003530329A (en)
AU (3) AU5322601A (en)
CA (1) CA2405151A1 (en)
WO (1) WO2001076531A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211863A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AU2002243204A1 (en) 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US6900192B2 (en) 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
ATE435035T1 (en) * 2003-01-13 2009-07-15 Bracco Imaging Spa IMPROVED LINKERS FOR RADIOPHARMACEUTICAL COMPOUNDS
EP2165709B1 (en) * 2004-08-02 2016-03-16 Ambrilia Biopharma Inc. Pharmaceutical compositions comprising a lysine based compound and an HIV antiviral or antiretroviral agent
JP2009530399A (en) * 2006-03-22 2009-08-27 シンデクサ ファーマシューティカルズ コーポレーション Compounds and methods for the treatment of diseases associated with ER stress
JP5201546B2 (en) * 2008-01-18 2013-06-05 学校法人近畿大学 N-acetylcysteine-conjugated bile acid, pharmaceutical composition containing the same and method for producing the same
US10350169B2 (en) 2014-10-31 2019-07-16 University Of Utah Research Foundation Compositions and methods for bile acid particles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012927A1 (en) * 1997-09-11 1999-03-18 Commonwealth Scientific And Industrial Research Organisation Purine acyclonucleosides as antiviral agents
WO2000058337A1 (en) * 1999-03-27 2000-10-05 Karo Bio Ab Liver specific bile acid derivatives of the glucocorticoid antagonist ru486
WO2001020331A1 (en) * 1999-09-14 2001-03-22 Xenoport, Inc. Substrates and screening methods for transport proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012927A1 (en) * 1997-09-11 1999-03-18 Commonwealth Scientific And Industrial Research Organisation Purine acyclonucleosides as antiviral agents
WO2000058337A1 (en) * 1999-03-27 2000-10-05 Karo Bio Ab Liver specific bile acid derivatives of the glucocorticoid antagonist ru486
WO2001020331A1 (en) * 1999-09-14 2001-03-22 Xenoport, Inc. Substrates and screening methods for transport proteins

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
KRAMER ET AL (ED PAUMGARTNER ET AL): "Bile Acids and the Hepatobiliary System (ISBN 0792388291)", 1993, KLUWER, DORDRECHT, NETHERLANDS, XP008056225 *
KRAMER W ET AL: "Bile acid derived HMG-CoA reductase inhibitors", BIOCHIMICA ET BIOPHYSICA ACTA - MOLECULAR BASIS OF DISEASE 1994 NETHERLANDS, vol. 1227, no. 3, 1994, pages 137 - 154, XP002355916, ISSN: 0925-4439 *
KRAMER W ET AL: "LIVER-SPECIFIC DRUG TARGETING BY COUPLING TO BILE ACIDS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 267, no. 26, 15 September 1992 (1992-09-15), pages 18598 - 18604, XP000453577, ISSN: 0021-9258 *
KRAMER W ET AL: "Modified bile acids as carriers for peptides and drugs", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 46, no. 1-2, 5 May 1997 (1997-05-05), pages 17 - 30, XP004096309, ISSN: 0168-3659 *
MILLS C O ET AL: "BILIARY EXCRETION OF CHENODEOXYCHOLYLLYSYLRHODAMINE IN WISTAR RATS A POSSIBLE ROLE OF A BILE ACID AS A CARRIER FOR DRUGS", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1126, no. 1, 1992, pages 35 - 40, XP002355917, ISSN: 0006-3002 *
See also references of WO0176531A3 *
STEPHAN Z F ET AL: "REDUCTION OF CARDIOVASCULAR AND THYROXINE-SUPPRESSING ACTIVITIES OFL-T3 BY LIVER TARGETING WITH CHOLIC ACID", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 43, no. 9, 8 May 1992 (1992-05-08), pages 1969 - 1974, XP000982833, ISSN: 0006-2952 *
SWAAN P W ET AL: "Enhanced transepithelial transport of peptides by conjugation to cholic acid", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 8, no. 4, 1997, pages 520 - 525, XP002158726, ISSN: 1043-1802 *

Also Published As

Publication number Publication date
JP2003530329A (en) 2003-10-14
EP1267898A2 (en) 2003-01-02
WO2001076531A3 (en) 2002-02-14
CA2405151A1 (en) 2001-10-18
WO2001076531A2 (en) 2001-10-18
AU2001253226B2 (en) 2006-06-08
AU5322601A (en) 2001-10-23
AU2006202213A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
IL151073A0 (en) Antiviral prodrugs
HUP0204092A3 (en) Novel bisamidate phosphononate prodrugs
SG93823A1 (en) Aryl-acrylic acid esters
HK1043667A1 (en) Structure for interlocking connectors
IL137956A0 (en) Acid labile prodrugs
AU6785401A (en) Novel dicarboxylic acid derivatives
EP1219662A4 (en) Polyamic acid ester
DE60140312D1 (en) Am methyl-d-erythriol phosphat reaktionsweg beteiligte gene
HK1047274A1 (en) Aminobenzoic acid derivatives
AU5322601A (en) Bile acid containing prodrugs with enhanced bioavailability
GB0025437D0 (en) Esters
AU2001249662A1 (en) 6-methoxy-2-naphthylacetic acid prodrugs
EP1340740A4 (en) Carboxylic acid type lipid
EP1343494A4 (en) Tetrapartate prodrugs
GB0129988D0 (en) Imidazolidineacetic acid derivatives
IL149258A0 (en) 6-methoxy-2-naphthylacetic acid prodrugs
IL148055A0 (en) Diffractive display
GB2353132B (en) Advertising board
HUP0402101A3 (en) Butyric acid derivatives
GB0025438D0 (en) Esters
GB0017435D0 (en) 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
GB0017682D0 (en) Novel phosphonocarboxylic acid esters
GB0019819D0 (en) Novel phosphonocarboxylic acid esters
GB9924911D0 (en) Novel phosphonocarboxylic acid esters
SI1261613T1 (en) Gastro-specific prodrugs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021007

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/50 19850101AFI20020306BHEP

Ipc: A61P 31/12 20000101ALI20051201BHEP

Ipc: C07J 43/00 19740701ALI20051201BHEP

Ipc: A61K 39/395 19850101ALI20051201BHEP

Ipc: A61K 39/44 19850101ALI20051201BHEP

Ipc: C07J 9/00 19740701ALI20051201BHEP

Ipc: A61K 39/42 19850101ALI20051201BHEP

Ipc: A61K 39/40 19850101ALI20051201BHEP

Ipc: C07J 41/00 19740701ALI20051201BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20051219

17Q First examination report despatched

Effective date: 20060731

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20081112